MedTrace Logo

A Phase 1 PK Study of Tolperisone in Healthy Subjects

NCT04465266 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2022-02-01

No results posted yet for this study

Summary

This is a randomized, single-blind, single and multiple dose crossover subjects in healthy adult subjects

Conditions

  • Healthy

Interventions

DRUG

Tolperisone

tablets

Sponsors & Collaborators

  • Neurana Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-07-28
Primary Completion
2020-08-21
Completion
2021-09-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04465266 on ClinicalTrials.gov